|
LT8672 is a synthetic 14-amino-acid research peptide with the sequence C-DEQERRRRRGRTR-NH2. The peptide contains an N-terminal cysteine followed by the arginine-rich sequence DEQERRRRRGRTR and is supplied with C-terminal amidation as an acetate salt.
The core sequence DEQERRRRRGRTR has been publicly disclosed as RMNE1-2 (SEQ ID NO: 3), a truncated peptide derived from the Neurogenin-1-associated RMNE1 sequence. RMNE1-related peptides have been investigated in research involving cellular permeability and melanin-associated biological processes. LT8672 differs from the publicly disclosed RMNE1-2 sequence by the addition of an N-terminal cysteine and C-terminal amidation.
The N-terminal cysteine provides a reactive sulfhydryl group that can be useful for thiol-selective conjugation, fluorescent labeling, carrier-protein coupling, surface immobilization, nanoparticle attachment, and other biochemical research applications. The peptide is highly enriched in arginine residues and may also be useful for studies involving arginine-rich peptides, peptide-cell interactions, cellular uptake, peptide conjugation, and structure-function relationships.
Reference: The sequence DEQERRRRRGRTR is disclosed as RMNE1-2, SEQ ID NO: 3, in patent publication WO2024048890A1, Composition containing peptides having skin-lightening effect, published March 7, 2024.
Note: The cited reference describes the DEQERRRRRGRTR sequence. LifeTein LT8672 contains an additional N-terminal cysteine and C-terminal amidation and therefore represents a modified synthetic peptide configuration.
|
